Result card

  • ETH3: What are the benefits and harms for patients, and what is the balance between the benefits and harms when implementing and when not implementing FIT? Who will balance the risks and benefits in practice and how?
English
No adaptation help available for this domain

What are the benefits and harms for patients, and what is the balance between the benefits and harms when implementing and when not implementing FIT? Who will balance the risks and benefits in practice and how?

Authors: Gottfried Endel

Internal reviewers: Pseudo165 Pseudo165, Pseudo220 Pseudo220, Pseudo263 Pseudo263, Pseudo296 Pseudo296, Pseudo88 Pseudo88

Results from EFF and SAF domain answer this question perfectly. As there are only minor differences between the two tests and the consequences are identical no important differences in benefits and risks have to be taken care of.

The key question is whether to implement a population based screening using the detection of fecal blood. Minor differences in sensitivity and specific do not shift the balance of risks and harms.

Important
Endel G Result Card ETH3 In: Endel G Ethical analysis In: Jefferson T, Cerbo M, Vicari N [eds.]. Fecal Immunochemical Test (FIT ) versus guaiac-based fecal occult blood test (FOBT) for colorectal cancer screening [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali; 2014. [cited 16 June 2021]. Available from: http://corehta.info/ViewCover.aspx?id=206